Skip to main content
. 2016 Jan 27;7(7):8321–8331. doi: 10.18632/oncotarget.7032

Table 1. Eleven high-confidencea non-synonymous variants identified by whole exomeb and targeted deep sequencingc.

Gene Chromosome Protein change Nucleotide change Mutation type QSS Mutant ratio Targeted sequencing
SETDB1 chr1 Y249X 747T>A nonsense 48 0.93 validated
DYSF chr2 R1604Q 4811G>A missense 111 0.83 not done
ATP2C1 chr3 W460R 1378T>A missense 99 0.86 not done
RAPGEF6 chr5 T325Sd 973A>T missense 51 0.85 validated
ACTB chr7 F262L 786C>G missense 37 0.35 validated
CASD1 chr7 V361L 1081G>T missense 39 0.62 not done
GOT1 chr10 T326I 977C>T missense 61 0.92 validated
GIT2 chr12 T28M 83C>T missense 43 0.88 not done
NOD2 chr16 Y240X 720T>A nonsense 39 0.92 validated
TP53 chr17 R282Wd 844C>T missense 37 0.96 validated
PSG1 chr19 E41Q 121G>C missense 42 0.84 not done
a

High-confidence is defined by quality score (QSS) greater than 30.

b

Whole exome sequencing was done on SOLiD 5500 (Life Technologies) using the TargetSeq Exome Enrichment kit (Life Technologies) as previously described. [32]

c

Targeted deep sequencing for validation was done on Ion Torrent PGM using a customized AmpliSeq panel (Life Technologies) as previously described. [32] (Average coverage > 2000X).

d

These mutations were confirmed by Sanger sequencing.